… ProQR Announces Conference Call to Discuss the Axiomer® RNA Editing Platform LEIDEN, Netherlands & CAMBRIDGE, Mass., … call and webcast to discuss the Company’s Axiomer RNA editing technology platform following the recently …
Partnership focused on utilizing Axiomer™ to develop editing oligonucleotides targeting an underlying genetic variant that causes Rett syndromeCollaboration expands ProQR’s commitment to advance the development of therapies for central nervous system diseases
… ProQR Announces Conference Presentations for Axiomer® RNA Editing Technology and QR-313 for DEB LEIDEN, the … ProQR will deliver a presentation on the Axiomer ® RNA editing technology during the TIDES: Oligonucleotide and …
… Presents in vivo Proof of Concept Data for the Axiomer® RNA Editing Platform Technology Key updates ProQR presents in … proof of concept for its novel and proprietary Axiomer ® RNA editing platform technology. Axiomer ® technology Editing …
… its clinical stage pipeline programs and the Axiomer ® RNA editing platform. ProQR leadership will highlight key … design and assumptions. The QR-421a, QR-1123, QR-504a, and RNA editing platform technologies will also be featured. …
Axiomer™ ADAR-mediated RNA editing pipeline advancing across liver and CNS programs, with CTA filing on track for Q2 2025 for lead program AX-0810 targeting NTCP for Cholestatic diseases Strengthened leadership with appointments of Chief Financial Officer and Chief
LEIDEN, Netherlands & CAMBRIDGE, Mass., May 12, 2025 (GLOBE NEWSWIRE) -- ProQR Therapeutics NV (Nasdaq: PRQR) (ProQR), a company dedicated to changing lives through transformative RNA therapies based on its proprietary Axiomer™ RNA editing technology platform, today announced that it will p
… highlighting the Company’s proprietary Axiomer ® RNA editing technology platform at upcoming scientific and … 15-16, 2023, in Basel, Switzerland; and the bi-annual RNA Editing Gordon Research Conference (GRC), March 19-24, …
Preclinical and translational pipeline program data for AX-0810 for Cholestatic Diseases targeting NTCP and AX-1412 for Cardiovascular Disease targeting B4GALT1 anticipated in 2024, building further momentum toward the clinicAccelerated development of Axiomer™ for CNS ap